DK1896059T3 - Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene - Google Patents

Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene

Info

Publication number
DK1896059T3
DK1896059T3 DK06795527.8T DK06795527T DK1896059T3 DK 1896059 T3 DK1896059 T3 DK 1896059T3 DK 06795527 T DK06795527 T DK 06795527T DK 1896059 T3 DK1896059 T3 DK 1896059T3
Authority
DK
Denmark
Prior art keywords
respiratory tract
tissue factor
inflammatory conditions
pathway inhibitor
conditions affecting
Prior art date
Application number
DK06795527.8T
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Application granted granted Critical
Publication of DK1896059T3 publication Critical patent/DK1896059T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
DK06795527.8T 2005-06-24 2006-06-23 Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene DK1896059T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Publications (1)

Publication Number Publication Date
DK1896059T3 true DK1896059T3 (da) 2013-04-08

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06795527.8T DK1896059T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene
DK06795540.1T DK1898945T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene
DK06808954.9T DK1906994T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af aktiveret protein C ved inflammatoriske tilstande, som angriber åndedrætsorganerne

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06795540.1T DK1898945T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene
DK06808954.9T DK1906994T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af aktiveret protein C ved inflammatoriske tilstande, som angriber åndedrætsorganerne

Country Status (15)

Country Link
US (3) US8088728B2 (da)
EP (3) EP1896059B1 (da)
JP (3) JP2008543926A (da)
KR (2) KR20080071116A (da)
CN (2) CN101262879B (da)
AU (2) AU2006273696B2 (da)
BR (2) BRPI0613137A2 (da)
CA (2) CA2612646C (da)
DK (3) DK1896059T3 (da)
HK (1) HK1114567A1 (da)
IL (2) IL188221A0 (da)
NO (2) NO20080433L (da)
RU (2) RU2496515C2 (da)
WO (3) WO2006136963A2 (da)
ZA (2) ZA200800251B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
EP3512539A4 (en) * 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5847085A (en) * 1996-11-08 1998-12-08 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
AU6053698A (en) * 1997-01-29 1998-08-18 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
CA2399267A1 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
JP2003521930A (ja) * 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1385535A2 (en) * 2001-05-02 2004-02-04 Novo Nordisk A/S Modified fvii in treatment of ards
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CA2463655A1 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CN100519721C (zh) * 2002-02-08 2009-07-29 Sk能源株式会社 清洁加热器管道的清洁剂和清洁方法
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
JP2006515882A (ja) 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
WO2004087148A1 (ja) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
CA2579884C (en) * 2004-09-10 2013-12-31 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
EP1799243B1 (en) 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
WO2006136963A3 (en) 2007-07-12
IL188221A0 (en) 2008-03-20
IL188220A0 (en) 2008-03-20
JP2013151510A (ja) 2013-08-08
CN101262879B (zh) 2013-04-10
US20100160218A1 (en) 2010-06-24
WO2006136963A2 (en) 2006-12-28
BRPI0611710A2 (pt) 2011-12-20
EP1906994A2 (en) 2008-04-09
JP2008543926A (ja) 2008-12-04
CA2612646A1 (en) 2006-12-28
WO2007012976A2 (en) 2007-02-01
CN101262880A (zh) 2008-09-10
CA2612597A1 (en) 2007-02-01
DK1898945T3 (da) 2013-03-25
EP1906994B1 (en) 2014-04-23
WO2007012976A3 (en) 2007-07-12
BRPI0613137A2 (pt) 2010-12-21
ZA200800251B (en) 2009-04-29
KR20080074085A (ko) 2008-08-12
AU2006260599A1 (en) 2006-12-28
US20100279925A1 (en) 2010-11-04
HK1114567A1 (en) 2008-11-07
EP1898945A2 (en) 2008-03-19
AU2006273696B2 (en) 2012-08-30
RU2008102655A (ru) 2009-07-27
EP1896059B1 (en) 2012-12-19
DK1906994T3 (da) 2014-07-21
RU2496515C2 (ru) 2013-10-27
WO2006136962A3 (en) 2007-07-12
CA2612646C (en) 2015-11-24
JP2008543925A (ja) 2008-12-04
AU2006273696A1 (en) 2007-02-01
US8088728B2 (en) 2012-01-03
RU2496516C2 (ru) 2013-10-27
NO20080433L (no) 2008-03-19
ZA200800255B (en) 2009-04-29
US20100297099A1 (en) 2010-11-25
CA2612597C (en) 2015-03-31
EP1898945B1 (en) 2012-12-19
NO20080434L (no) 2008-03-17
RU2008102656A (ru) 2009-07-27
KR20080071116A (ko) 2008-08-01
WO2006136962A2 (en) 2006-12-28
EP1896059A2 (en) 2008-03-12
CN101262879A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
EE00721U1 (et) Inhalaatori loendur
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
DK1996557T3 (da) Pyridazinon-forbindelse og anvendelse deraf som herbicid
ATE534421T1 (de) Vernebler
BRPI0716318A2 (pt) Faixa compressora
DK2277509T3 (da) DPP IV inhibitorformuleringer
ITMI20060184U1 (it) Deambulatore magico
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
ATE502666T1 (de) Inhalator
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2214677T3 (da) Sammensætninger til behandling af inflammation i mavetarmkanalen
DK2018158T3 (da) Ny racecadotril administrationsform
DE602007002345D1 (de) Kompressor
DE602005026122D1 (de) Inhalator
ATE448431T1 (de) Chirurgische kassette
DE602007013317D1 (de) Inhalator
DK2056858T3 (da) Behandling af lungesygdomstilstande
NO20083139L (no) Anvendelse av hyllebærekstrakt
FI20061064A0 (fi) Uudet ohutkalvorakenteet
DK1896059T3 (da) Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene
DK2120919T3 (da) Ny kombination til anvendelse ved behandling af inflammatoriske lidelser
DE602007004293D1 (de) Verdichter